Accelerator mass spectrometry analysis of background 14C- concentrations in human blood: Aiming at reference data for further microdosing studies

Annals of Nuclear Medicine

Volumn 22, Issue 10, 2008, Pages 883-889

  Minamimoto, Ryogo ^a   Hamabe, Yoshimi ^b   Miyaoka, Teiji ^b   Hara, Takamitsu ^b   Yoshida, Keisuke ^a   Oka, Takashi ^a,c   Inoue, Tomio ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Institute of Accelerator Analysis (IAA) Ltd   (Japan)

^c Bay Bio Imaging (BBI) Co Ltd   (Japan)

Author keywords

14C; Accelerator mass spectrometry; Background; Microdose; Phase 0 clinical study

Indexed keywords

CARBON 14;

ADULT; ARTICLE; BLOOD CLOT; FEMALE; HUMAN; ISOTOPE ANALYSIS; JAPANESE; MALE; MASS SPECTROMETRY; MICRODOSIMETRY; NORMAL HUMAN; PRIORITY JOURNAL; RADIATION DETECTION; RADIATION DOSE; RADIATION MEASUREMENT; REFERENCE VALUE;

ADULT; BACKGROUND RADIATION; BLOOD CHEMICAL ANALYSIS; CARBON RADIOISOTOPES; FEMALE; HUMANS; JAPAN; MALE; MASS SPECTROMETRY; MIDDLE AGED; PARTICLE ACCELERATORS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 58249120534     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-008-0200-x     Document Type: Article

References (23)

1. J.S. Vogel K.W. Turteltaub 1998 Accelerator mass spectrometry as a bioanalytical tool for nutritional research Adv Exp Med Biol 445 397 410
2. R.C. Garner J. Barker C. Flavell J.V. Garner M. Whattam G.C. Young 2000 A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14Clabelled drugs in plasma, urine and faecal extracts J Pharm Biomed Anal 24 197 209
3. D.E. Nelson R.G. Korteling W.R. Stott 1977 Carbon-14: direct detection at natural concentration Science 198 507 508
4. C.L. Bennett R.P. Beukens M.R. Clover H.E. Gove R.B. Liebert A.E. Litherland 1977 Radiocarbon dating using electrostatic accelerators: negative ions provide the key Science 198 508 510
5. T. Miyaoka Y. Isono K. Setani K. Sakai I. Yamada Y. Sato 2007 Bioanalysis works in the IAA AMS facility: comparison of AMS analytical method with LSC method in human mass balance study Nucl Instr Methods Phys Res B259 779 785
6. J.S. Vogel K.W. Turteltaub R. Finkel D.E. Nelson 1995 Accelerator mass spectrometry Anal Chem 67 353A 359A
7. B. Kaye R.C. Garner R.J. Mauthe S.P. Freeman K.W. Turteltaub 1997 A preliminary evaluation of accelerator mass spectrometry in the biomedical field J Pharm Biomed Anal 16 541 543
8. Japan Pharmaceutical Manufactures Association. DATA BOOK 2000. Tokyo: Japan Pharmaceutical Manufactures Association; 2000. p 1-42.
9. The European Agency for the Evaluation of Medical products. Evaluation of Medicines for Human Use (EMEA), Committee for Proprietary Medicinal Products (CPMP). Position paper on non-clinical safety studies to support clinical trials with a single microdose, CPMP/SWP/2599/02, London, 23 January 2003; revised edition: CPMP/SWP/2599/02/Rev 1, London, 23 June 2004.
10. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, investigators and reviewers, exploratory IND studies, 12 January 2006.
11. H. Kitagawa T. Masuzawa T. Nakamura E. Matsumoto 1993 A batch preparation method for graphite targets with low background for AMS 14C measurements Radiocarbon 35 295
12. R. Twombly 2006 Slow start to Phase 0 as researchers debate value J Natl Cancer Drugs 9 115 122
13. Goodall S. Raising to the productivity challenge: a strategic framework for Biopharma. Boston Consulting Group Report. 2004. http://www.bcg.com/ publications/files/rising-to-the-productivity-challenge.pdf.
14. G. Lappin R.C. Garner 2003 Big physics, small doses: the use of AMS and PET in human microdosing of development drugs Nat Rev Drug Discov 2 233 240
15. R.D. Combes T. Berridge J. Connelly M.D. Eve R.C. Garner S. Toon 2003 Early microdose drug studies in human volunteers can minimise animal testing: proceedings of a workshop organised by volunteers in research and testing Eur J Pharm Sci 19 1 11
16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 21 July 2005.
17. R.C. Garner 2000 Accelerator mass spectrometry in pharmaceutical research and development: a new ultrasensitive analytical method for isotope measurement Curr Drug Metab 1 205 213
18. The European Agency for the Evaluation of Medical Products. Evaluation of Medicines for Human Use (EMEA), Committee for Proprietary Medicinal Products (CPMP). Concept paper on the development of CHMP guideline on the non-clinical requirement to support early phase I:. clinical trials with pharmaceutical compounds London, 23 March 2006 Doc. Ref. EMEA/CHMP/SWP/91850/2006.
19. S. Marchetti J.H. Schellens 2007 The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials Br J Cancer 97 577 581
20. G. Lappin W. Kuhnz R. Jochemsen J. Kneer A. Chaudhary B. Oosterhuis 2006 Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs Clin Pharmacol Ther 80 203 215
21. 14C levels in Japan in 1990s Radioisotopes 51 381 391
22. D.S. Harkness A. Walton 1969 Carbon-14 in the biosphere and humans Nature 223 1216 1218
23. G. Young W. Ellis J. Ayrton E. Hussey B. Adamkiewicz 2001 Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique Xenobiotica 31 619 632